Shuttle Pharmaceuticals Holdings (SHPH) Research & Development (2021 - 2026)

Shuttle Pharmaceuticals Holdings' Research & Development history runs 6 years deep, the most recent figure standing at $267240.0 for Q1 2026.

• In Q1 2026, Research & Development fell 83.02% year-over-year to $267240.0; the TTM figure through Mar 2026 stood at $2.8 million (down 38.8% YoY), while the FY2025 annual figure was $4.1 million, up 12.05% from the prior year.
• Research & Development was $267240.0 for Q1 2026 at Shuttle Pharmaceuticals Holdings, down from $554831.0 in the prior quarter.
• In the past five years, Research & Development ranged from a high of $1.6 million in Q1 2025 to a low of -$1436.0 in Q4 2022.
• Historically, Research & Development has averaged $734440.3 across 5 years, with a median of $693356.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Research & Development tumbled 100.32% in 2022, then soared 48383.84% in 2023.
• A 5-year view of Research & Development shows it stood at -$1436.0 in 2022, then jumped by 48383.84% to $693356.0 in 2023, then soared by 42.27% to $986409.0 in 2024, then tumbled by 43.75% to $554831.0 in 2025, then sank by 51.83% to $267240.0 in 2026.
• The last three Research & Development figures came in at $267240.0 (Q1 2026), $554831.0 (Q4 2025), and $943478.0 (Q3 2025), per Business Quant data.